Cleavage and polyadenylation specificity factor (CPSF) -derived peptides can induce HLA-A2-restricted and tumor-specific CTLS in the majority of gastrointestinal cancer patients

International Journal of Cancer

Volumn 99, Issue 3, 2002, Pages 409-417

  Maeda, Yoshiaki ^a,b   Ito, Masaaki ^a   Harashima, Nanae ^a   Nakatsura, Tetsuya ^a   Hida, Naoya ^a   Imai, Nobue ^a   Sato, Yuuji ^b   Shichijo, Shigeki ^a   Todo, Satoru ^b   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CTL; Immunotherapy; MHC; Tumor immunity, vaccination

Indexed keywords

CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; HLA A2 ANTIGEN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; BLOTTING, NORTHERN; CANCER VACCINES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; PEPTIDES; RNA-BINDING PROTEINS; SEPHAROSE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0037140934     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10377     Document Type: Article

References (38)

1. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma
2. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes
3. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vitro tumor rejection
4. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma
5. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
6. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognized the same HER2/neu-derived peptide
7. Identification of an immunodominant peptide of HER2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes line
8. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
9. Generation of human cytotoxic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
10. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes
11. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restructed Cytotoxic T lymphocytes in cancer patients
12. Identification of SART3-derived peptides capable of inducing HLA-A2-restriced and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes
13. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes
14. Identification of Cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-ristricted and tumor-specific cytotoxic T lymphocytes
15. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma
16. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases
17. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer
18. + cancers
19. Tumor regressions observed in patients with metastatic melanoma treated with an antigen peptide encoded by MAGE-3 and presented by HLA-A1
20. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
21. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells
22. Frequent cytotoxic T-cell responses to peptide MAGE-A10254-262 in melanoma
23. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12
24. + T cells after vaccination with antigenic peptide
25. Interdermal ras peptide vaccination with granulocytemacropharge colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
26. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
27. Descriptive epidemiology: Cancer statistics
28. Cancer incidence and incidence rates in Japan in 1995: Estimates based on data from nine population-based cancer registries
29. Allele and haprotype frequencies for HLA and complement loci in various ethnic groups
30. Genetic diversity of HLA-A2: Evolutionary and functional significance
31. Molecular Basis of T cell-mediated recognition of pancreatic cancer cells
32. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTLs
33. Scheme for ranking potential HLA-A2 peptide based on independent binding of individual peptide side-chains
34. MHC ligands and peptide motifs
35. The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3′-end formation
36. RNA ligands selected by Cleavage and Polyadenylation Factor contain direct sequence motifs that function as downstream elements in 3′-end processing of pre-mRNA
37. A subset of Poly(A) Polymerase is concentrated at sites of RNA synthesis and is associated with domains enriched in splicing factors and poly(A) RNA
38. Nuclear domains enriched in RNA 3′-processing factors associate with coiled bodies and histone genes in a cell cycle-dependent manner